France seeks quick resumption of AstraZeneca shots suspended over safety
fears
Send a link to a friend
[March 16, 2021]
By Giulia Segreti and Caroline Copley
ROME/BERLIN (Reuters) - France expressed
hope European medical experts would clear up questions over the safety
of AstraZeneca's COVID-19 shot on Thursday, as experts warned the
decision by major European states to stop using it posed a greater risk
to public health.
In a coordinated step, the European Union's largest members - Germany,
France and Italy - suspended the use of AstraZeneca's vaccine on Monday
pending the outcome of an investigation by the bloc's medicines
regulator into isolated cases of bleeding, blood clots and low platelet
counts.
They were joined by Sweden and Latvia on Tuesday, bringing to more than
a dozen the number of EU countries that have acted since reports first
emerged of thromboembolisms affecting people after they got the
AstraZeneca shot.

The World Health Organization and European Medicines Agency have joined
AstraZeneca in saying there is no proven link.
"The choice is a political one," Nicola Magrini, the director general of
Italy's medicines authority AIFA told daily la Repubblica in an
interview.
Magrini called the AstraZeneca vaccine safe and said its benefit to risk
ratio was "widely positive". There have been eight deaths and four cases
of serious side-effects following vaccinations in Italy, he added.
French Health Minister Olivier Veran also told reporters that the
risk-reward ratio for the vaccine remained positive.
"We expect some kind of verdict from the European scientific community
by Thursday afternoon, allowing us to resume the campaign," Veran said.
France's vaccination chief Alain Fischer said he expected the suspension
to be temporary.
[to top of second column]
|

A view shows vials of the AstraZeneca COVID-19 vaccine in a box at a
medical center in Champigny, near Paris, as France's decision to
suspend temporarily the AstraZeneca COVID-19 vaccine was taken in
co-ordination with other European countries, March 16, 2021.
REUTERS/Gonzalo Fuentes

Governments say they acted out of an abundance of caution, with
German Health Minister Jens Spahn stating on Monday that the
decision to suspend AstraZeneca was not political but based on
expert advice.
He acted after Germany's vaccine watchdog identified a unusual
number of cases of a rare cerebral vein thrombosis. Out of 1.6
million people in Germany who had got the AstraZeneca, seven fell
ill and three died.
The risk of dying of COVID is still orders of magnitude greater,
especially among those most vulnerable such as the elderly, said
Dirk Brockmann, an epidemiologist at the Robert Koch Institute for
Infectious diseases.
"In the risk groups the risk of dying of COVID is much, much higher.
That means one is probably 100,000 times more likely to die of COVID
than because of an AstraZeneca vaccine," Brockmann told ARD public
television.
(Additional reporting by Sudip Kar-Gupta and Matthieu Protard in
PARIS; writing by Douglas Busvine; editing by Philippa Fletcher)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
 |